FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	OVAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schneebaum Marc R (Last) (First) (Middle) C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 400					2. Issuer Name and Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS, INC. [MDGL] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2018 4. If Amendment, Date of Original Filed (Month/Day/Year)									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) below) Chief Financial Officer Individual or Joint/Group Filing (Check Applicable)					
WEST PA 19428 CONSHOHOCKEN														Line)	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-	-Deriva	tive S	Securiti	es A	cqu	uired, Di	ispo	sed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/L						eemed ution Date, th/Day/Year)		Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a			5. Amour Securitie Beneficia Owned F	es Form ally (D) (Following (I) (I		: Direct C r Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership		
								Code V	Α	Amount	(A) o (D)	r Pr	ice	Transact (Instr. 3 a	ion(s)			Instr. 4)	
		-	Table II - D						red, Dis options,						Owned	'			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)	Co	ansactio	on of tr. Deriv Secu Acqu (A) or Dispo	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Со	ode V	(A)	(D)		ate xercisable	Exp Date	expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (Right to Buy)	\$124.45	03/01/2018		A	A	28,00	0		(1)	03/0	01/2028	Common Stock	28,0	000	\$0	28,000)	D	

Explanation of Responses:

1. The option vests as to 25% of the shares on the first anniversary of the date of grant (March 1, 2019) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date.

/s/ Michael Lawhead, as

attorney-in-fact for Marc R.

Schneebaum

** Signature of Reporting Person

03/05/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.